Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jun;22(3):211-9.
doi: 10.3747/co.22.2447.

Systemic therapy for recurrent, persistent, or metastatic cervical cancer: a clinical practice guideline

H Hirte  1 , E B Kennedy  2 , L Elit  1 , M Fung Kee Fung  3
Affiliations

Systemic therapy for recurrent, persistent, or metastatic cervical cancer: a clinical practice guideline

H Hirte et al. Curr Oncol. 2015 Jun.

Abstract

Background: Systemic therapy options are needed for women with recurrent, metastatic, or persistent cervical cancer. This systematic review and clinical practice guideline were developed to address that need, and to update a 2007 guideline from Cancer Care Ontario's Program in Evidence-Based Care.

Methods: The literature between 2006 and April 2014 in the medline and embase databases, the Cochrane Database of Systematic Reviews (Issue 4, 2014), the Cochrane Central Register of Controlled Trials (Issue 3, 2014), relevant guideline databases, and conference proceedings of the American Society of Clinical Oncology (2007-2013) was searched. A working group developed draft guidelines and incorporated comments and feedback from internal and external reviewers.

Results: Four phase iii randomized controlled trials met the inclusion criteria for the review and provided the basis for draft recommendations. Feedback was obtained from Ontario practitioners and others abroad, which led to modifications to the draft recommendations. Three key recommendations were developed.

Conclusions: The working group concluded that all patients should be offered the opportunity to participate in appropriate randomized clinical trials. Cisplatin-paclitaxel, cisplatin-vinorelbine, cisplatin-gemcitabine, and cisplatin-topotecan are recommended combinations for this patient population. The substitution of carboplatin for cisplatin in the foregoing combinations can also be recommended because carboplatin is associated with fewer adverse effects and greater ease of administration. Selection of combination chemotherapy will depend on the toxicity profile, patient preference, and other factors. Finally, bevacizumab in combination with cisplatin-paclitaxel or carboplatin-paclitaxel is recommended for a specific subset of the target population as outlined in Gynecologic Oncology Group study 0240.

Keywords: Cervical cancer; chemotherapy; practice guideline; systematic review; systemic therapy.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Literature search flow diagram. The search strategy in Table I was applied for the period 2006 to April 2014.
See this image and copyright information in PMC

References

    1. Canadian Cancer Society’s Steering Committee on Cancer Statistics . Canadian Cancer Statistics. Toronto, ON: Canadian Cancer Society; 2013. 2013.
    1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96. doi: 10.3322/CA.2007.0010. - DOI - PubMed
    1. Hirte HW, Strychowsky JE, Oliver T, Fung-Kee-Fung M, Elit L, Oza AM. Chemotherapy for recurrent, metastatic, or persistent cervical cancer: a systematic review. Int J Gynecol Cancer. 2007;17:1194–204. doi: 10.1111/j.1525-1438.2007.00900.x. - DOI - PubMed
    1. Kitagawa R, Katsumata N, Ando M, et al. A multi-institutional phase ii trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer. Gynecol Oncol. 2012;125:307–11. doi: 10.1016/j.ygyno.2012.02.009. - DOI - PubMed
    1. Monk BJ, Sill MW, McMeekin DS, et al. Phase iii trial of four cisplatin-containing doublet combinations in stage ivb, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2009;27:4649–55. doi: 10.1200/JCO.2009.21.8909. - DOI - PMC - PubMed

LinkOut - more resources